Drugs Made In America Acquisition Corp. (DMAAU) Preferred Stock Liabilities (2025)
Drugs Made In America Acquisition's (DMAAU) quarterly Preferred Stock Liabilities came in at $239.9 million in Q4 2025, up 0.97% on a QoQ basis from $237.6 million in Q3 2025.
Drugs Made In America Acquisition Corp. (DMAAU) Preferred Stock Liabilities (2025) Analysis & Trends
Drugs Made In America Acquisition (DMAAU) has 1 years of Preferred Stock Liabilities data on file, last reported at $239.9 million in Q4 2025.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $239.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $239.9 million (changed N/A YoY) and the FY2025 annual result came in at $239.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities grew to $239.9 million in Q4 2025, from $237.6 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $239.9 million in Q4 2025 to a low of $232.7 million in Q1 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 239.91 Mn |
| Sep 30, 2025 | 237.60 Mn |
| Jun 30, 2025 | 235.16 Mn |
| Mar 31, 2025 | 232.74 Mn |